Ipsen's Dysport hits primary endpoint in chronic migraine Phase 3
C-BEOND met its week-24 monthly-migraine-day endpoint versus placebo, positioning Dysport as a candidate first-in-class botulinum toxin across both migraine types.
Executive Summary
- Ipsen's Phase 3 chronic migraine trial for Dysport met its primary endpoint, reducing monthly migraine days versus placebo, with safety consistent with the drug's established profile.
- Chronic migraine already has an approved botulinum toxin option, so this result establishes Dysport as a second mechanism-matched candidate rather than opening a new treatment category.
- The result lands alongside a positive readout in the companion episodic migraine trial, extending the same drug across both migraine populations if both hold up under detailed data.
- The topline announcement withholds the effect size and statistical detail, so the case for differentiation against the existing standard of care will turn on data still to come.
The readout
Ipsen announced on July 9, 2026 that C-BEOND (NCT06047444), a 759-patient, placebo-controlled Phase 3 trial, met its primary endpoint: the change from baseline in monthly migraine days (MMD) at week 24, measured over weeks 21 to 24. The company called the reduction statistically significant and said the safety profile was consistent with Dysport's established use in its approved indications, with no new signals identified. The trial enrolled adults with a chronic migraine diagnosis of more than 12 months' standing and at least 15 monthly headache days, run across sites in the United States, Canada, and seven European countries. NCT06047444+1A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in AdultsNCT06047444Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both ...Jul 9, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The design
C-BEOND is a randomized, placebo-controlled Phase 3 trial run under an Experimental-versus-Placebo-Comparator design. It enrolled to its target of 759 patients, with the primary completion date landing May 21, 2026 after several administrative revisions to the registry timeline. The trial carries 24 secondary endpoints, including migraine-specific quality-of-life and headache-impact measures, alongside the monthly migraine day reduction that anchors the primary result. Ipsen has not yet disclosed the effect size, p-value, or confidence interval behind the topline claim, and said detailed findings from the BEOND program will be presented at a future scientific congress. NCT06047444+1A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in AdultsNCT06047444Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both ...Jul 9, 2026
Program breadth
The same disclosure carried a positive result from E-BEOND (NCT06047457), Ipsen's companion Phase 3 trial testing Dysport in episodic migraine, a substantially larger patient population defined by fewer headache days per month. Ipsen's own framing calls this the first Phase 3 program to show efficacy of a botulinum toxin across both episodic and chronic migraine, a claim tied to the E-BEOND result specifically, since chronic migraine already has an approved botulinum toxin option on the market. Christelle Huguet, Ipsen's EVP and Global Head of R&D, said the results "position Dysport as a potential first-in-class treatment for a broad migraine population," a claim that applies to the combined episodic-chronic label ambition rather than the chronic migraine indication alone. DysportDysport® is the first botulinum toxin to achieve positive topline Phase III results in both ...Jul 9, 2026
The competitive frame
Within SNAP-25-targeting botulinum toxin trials for chronic migraine, Merz Pharmaceuticals is running a direct comparator program, Xeomin (incobotulinumtoxinA), in a Phase 3 trial (NCT07018713) with a primary completion date in October 2027. Ipsen also has its own episodic migraine trial for the same drug (NCT06047457) as its nearest same-molecule precedent. Outside the botulinum toxin class, the migraine field is populated by CGRP-targeting mechanisms, including gepants and monoclonal antibodies in Phase 4 study across multiple sponsors, none of which share Dysport's SNAP-25 target or acetylcholine-release-inhibitor mechanism.
Trial history
The registry shows a lengthy timeline history: the primary completion date moved six times since first posting in September 2023, shifting from an original June 2025 target out to June 2026 before pulling back in to May 21, 2026 as enrollment closed. Enrollment grew from 720 to 759 patients as an actual count once recruitment ended, a change the trial's own operational baseline model classifies as within the routine range and not a departure from typical Phase 3 registry behavior. The trial moved to Active, not recruiting status in October 2025 once enrollment finished, consistent with a program that filled to target and proceeded through primary completion without alarm. NCT06047444A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in AdultsNCT06047444
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.